Angela Tincani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9267107/publications.pdf

Version: 2024-02-01

		12322	12933
326	20,636	69	131
papers	citations	h-index	g-index
333	333	333	14494
333	333	333	11171
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and Rheumatism, 2002, 46, 1019-1027.	6.7	1,736
2	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.5	1,265
3	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases, 2016, 75, 795-810.	0.5	780
4	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.5	664
5	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	0.6	573
6	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases, 2014, 73, 17-23.	0.5	471
7	Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research and Therapy, 2006, 8, 209.	1.6	469
8	Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmunity Reviews, 2010, 9, 709-715.	2.5	469
9	Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. Arthritis and Rheumatism, 2001, 44, 1832-1835.	6.7	435
10	Covid-19 and autoimmunity. Autoimmunity Reviews, 2020, 19, 102597.	2.5	418
11	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.5	268
11	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561. Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878.	0.5 6.7	268 250
	definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561. Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001,		
12	definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561. Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid	6.7	250
12 13	definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561. Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with	6.7	250 224
12 13	definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561. Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology, 2011, 50, 1684-1689.	6.7 2.5 0.9	250 224 193
12 13 14	definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561. Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology, 2011, 50, 1684-1689. Immunization with Anticardiolipin Cofactor (Beta-2-Glycoprotein I) Induces Experimental Antiphospholipid Syndrome in Naive Mice. Journal of Autoimmunity, 1994, 7, 441-455. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome.	6.7 2.5 0.9	250 224 193

#	Article	IF	CITATIONS
19	Anticardiolipin Antibody Assay: a Methodological Analysis for a better Consensus in Routine Determinations. Thrombosis and Haemostasis, 2001, 86, 575-583.	1.8	177
20	State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmunity Reviews, 2015, 14, 376-386.	2.5	169
21	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. American Journal of Kidney Diseases, 2001, 37, 490-498.	2.1	168
22	Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?. Lupus, 1995, 4, 122-130.	0.8	165
23	International consensus guidelines on anticardiolipin and anti–β ₂ â€glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis and Rheumatism, 2012, 64, 1-10.	6.7	163
24	14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Autoimmunity Reviews, 2014, 13, 795-813.	2.5	161
25	The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmunity Reviews, 2015, 14, 498-502.	2.5	152
26	Differential Effects of Anti–β2-Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome. Circulation, 1998, 97, 900-906.	1.6	150
27	The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of Autoimmunity, 2017, 76, 10-20.	3.0	146
28	Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. Journal of the Neurological Sciences, 2001, 184, 33-39.	0.3	139
29	Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thrombosis Research, 2004, 114, 553-558.	0.8	138
30	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Frontiers in Immunology, 2020, 11, 584241.	2.2	137
31	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134
32	Novel aspects of Sjögren's syndrome in 2012. BMC Medicine, 2013, 11, 93.	2.3	134
33	Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis and Rheumatism, 1996, 39, 758-766.	6.7	132
34	Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology, 2009, 214, 877-886.	0.8	132
35	Follow-Up of Infants Exposed to Hydroxychloroquine Given to Mothers during Pregnancy and Lactation. Journal of Perinatology, 2005, 25, 86-89.	0.9	129
36	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology, 2015, 54, 891-898.	0.9	129

#	Article	IF	CITATIONS
37	Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Reviews, 2021, 46, 100745.	2.8	129
38	Th2 immune deviation induced by pregnancy: The two faces of autoimmune rheumatic diseases. Reproductive Toxicology, 2006, 22, 234-241.	1.3	126
39	Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Research and Therapy, 2012, 14, R97.	1.6	124
40	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. Autoimmunity Reviews, 2015, 14, 387-395.	2.5	121
41	Inter-laboratory Variability of Anti-Î ² 2-glycoprotein I Measurement. Thrombosis and Haemostasis, 2002, 88, 66-73.	1.8	115
42	Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology, 2011, 50, 657-664.	0.9	112
43	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. Journal of the American Society of Nephrology: JASN, 2014, 25, 2483-2498.	3.0	112
44	Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. Journal of Immunological Methods, 2016, 433, 1-5.	0.6	109
45	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 115-123.	1.5	107
46	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmunity Reviews, 2019, 18, 406-414.	2.5	106
47	COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study. Lancet Rheumatology, The, 2020, 2, e549-e556.	2.2	105
48	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thrombosis and Haemostasis, 2014, 112, 727-735.	1.8	102
49	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunologic Research, 2017, 65, 17-24.	1.3	97
50	Exosome-delivered microRNAs promote IFN- \hat{l}_{\pm} secretion by human plasmacytoid DCs via TLR7. JCI Insight, 2018, 3, .	2.3	96
51	Autoantibodies in lupus: Culprits or passive bystanders?. Autoimmunity Reviews, 2012, 11, 596-603.	2.5	95
52	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β ₂ â€Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. Arthritis and Rheumatology, 2015, 67, 2196-2204.	2.9	94
53	Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-Î ² 2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1997, 73, 37-42.	0.5	91
54	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology, 2012, 51, 157-168.	0.9	89

#	Article	IF	Citations
55	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. Journal of Autoimmunity, 2016, 74, 6-12.	3.0	89
56	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
57	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. Journal of Autoimmunity, 2018, 86, 1-8.	3.0	86
58	Features associated with epilepsy in the antiphospholipid syndrome. Journal of Rheumatology, 2004, 31, 1344-8.	1.0	86
59	Anti-Â2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Annals of the Rheumatic Diseases, 2011, 70, 380-383.	0.5	85
60	European registry of babies born to mothers with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2013, 72, 217-222.	0.5	84
61	Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunologic Research, 2014, 60, 170-176.	1.3	84
62	Renal Involvement in Primary Antiphospholipid Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1211-1217.	2.2	83
63	Patients with antiphospholipid syndrome display endothelial perturbation. Journal of Autoimmunity, 2010, 34, 105-110.	3.0	82
64	HLA class II alleles associations of anticardiolipin and anti b2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus, 2000, 9, 47-55.	0.8	80
65	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. Journal of Autoimmunity, 2016, 74, 194-200.	3.0	80
66	Type I interferons in systemic autoimmunity. Autoimmunity, 2010, 43, 196-203.	1.2	78
67	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	1.0	77
68	Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis and Rheumatism, 2004, 50, 1549-1560.	6.7	72
69	Vitamin D Endocrine System and the Immune Response in Rheumatic Diseases. Vitamins and Hormones, 2011, 86, 327-351.	0.7	72
70	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
71	Anticardiolipin Antibodies in Infections are Heterogenous in Their Dependency on \hat{l}^2 2-Glycoprotein I: Analysis of Anticardiolipin Antibodies in Leprosy. Lupus, 1994, 3, 515-521.	0.8	71
72	Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. Journal of Autoimmunity, 2012, 38, J197-J208.	3.0	69

#	Article	IF	Citations
73	Sex gender and autoimmunity. Journal of Autoimmunity, 2012, 38, J71-J73.	3.0	67
74	Association of <i>STAT4</i> and <i>BLK</i> , but not <i>BANK1</i> or <i>IRF5</i> , with primary antiphospholipid syndrome. Arthritis and Rheumatism, 2009, 60, 2468-2471.	6.7	66
75	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Thrombosis and Haemostasis, 2016, 115, 285-290.	1.8	66
76	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	1.8	66
77	Prevalence of hepatitis C serum antibody in autoimmune diseases. Journal of Autoimmunity, 2009, 32, 261-266.	3.0	65
78	Antimalarial agents in pregnancy. Lancet, The, 2002, 359, 524-525.	6.3	64
79	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
80	Dendritic Cells Preferentially Internalize Apoptotic Cells Opsonized by Anti- \hat{l}^2 2-glycoprotein I Antibodies. Journal of Autoimmunity, 1998, 11, 403-411.	3.0	63
81	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	2.5	63
82	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. Autoimmunity Reviews, 2017, 16, 730-734.	2.5	63
83	Variability of anti- \hat{l}^2 2 glycoprotein I antibodies measurement by commercial assays. Thrombosis and Haemostasis, 2005, 94, 665-672.	1.8	62
84	Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 666-672.	1.0	62
85	Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?. Autoimmunity Reviews, 2015, 14, 23-29.	2.5	62
86	A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus. Journal of Autoimmunity, 2016, 74, 106-117.	3.0	62
87	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thrombosis and Haemostasis, 2018, 47, 639-646.	1.8	62
88	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	2.5	62
89	Involvement of renal tubular toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis and Rheumatism, 2007, 56, 1569-1578.	6.7	61
90	Lupus and the Antiphospholipid Syndrome in Pregnancy and Obstetrics: Clinical Characteristics, Diagnosis, Pathogenesis, and Treatment. Seminars in Thrombosis and Hemostasis, 2008, 34, 267-273.	1.5	60

#	Article	IF	Citations
91	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. Journal of Autoimmunity, 2018, 90, 1-27.	3.0	60
92	Beyond thrombosis: Anti- \hat{l}^2 2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. Journal of Autoimmunity, 2018, 90, 76-83.	3.0	60
93	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	1.5	60
94	Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus, 2013, 22, 1327-1335.	0.8	59
95	Standards and reference materials for the anticardiolipin and anti- \hat{l}^2 2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clinica Chimica Acta, 2012, 413, 358-360.	0.5	58
96	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). Journal of the American Society of Nephrology: JASN, 2015, 26, 1905-1924.	3.0	58
97	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Realâ€Life Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
98	Anticardiolipin and anti- \hat{l}^2 2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 1999, 28, 344-351.	0.6	57
99	Infertility in women with systemic autoimmune diseases. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101369.	2.2	56
100	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clinical and Experimental Rheumatology, 2015, 33, 449-56.	0.4	55
101	Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. American Journal of Obstetrics and Gynecology, 1993, 169, 423-426.	0.7	53
102	Clinical Significance of IgA Anti-Cardiolipin and IgA Anti- \hat{l}^2 2Glycoprotein I Antibodies. Current Rheumatology Reports, 2013, 15, 343.	2.1	53
103	Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Medicine, 2014, 12, 38.	2.3	53
104	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology, 2020, 59, 1306-1314.	0.9	53
105	Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma. Journal of Rheumatology, 2010, 37, 2071-2075.	1.0	52
106	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open, 2019, 5, e000924.	1.8	52
107	AutoAbSC.Org — Autoantibody Standardization Committee in 2006. Autoimmunity Reviews, 2007, 6, 577-580.	2.5	51
108	Helicobacter pylori serology in autoimmune diseases – fact or fiction?. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1075-82.	1.4	51

#	Article	IF	Citations
109	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. Journal of Rheumatology, 2017, 44, 1165-1172.	1.0	51
110	Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity?. Journal of Autoimmunity, 2008, 30, 51-57.	3.0	50
111	Aicardi–Goutieres syndrome, a rare neurological disease in children: A new autoimmune disorder?. Autoimmunity Reviews, 2013, 12, 506-509.	2.5	50
112	Classical Examples of the Concept of the ASIA Syndrome. Biomolecules, 2020, 10, 1436.	1.8	50
113	Anticardiolipin and Anti-Beta2 Glycoprotein I Antibodies in Infants Born to Mothers with Antiphospholipid Antibody-Positive Autoimmune Disease: A Follow-Up Study. American Journal of Perinatology, 2006, 23, 247-252.	0.6	48
114	Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. Arthritis Care and Research, 2016, 68, 738-743.	1.5	48
115	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	2.3	48
116	Pregnancy and autoimmunity: Maternal treatment and maternal disease influence on pregnancy outcome. Autoimmunity Reviews, 2005, 4, 423-428.	2.5	47
117	Pregnancy in patients with autoimmune disease: A reality in 2016. Autoimmunity Reviews, 2016, 15, 975-977.	2.5	47
118	Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmunity Reviews, 2009, 8, 580-584.	2.5	46
119	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity Reviews, 2015, 14, 686-691.	2.5	46
120	Laboratory criteria of the obstetrical antiphospholipid syndrome. Thrombosis and Haemostasis, 2009, 102, 25-28.	1.8	45
121	European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO). Autoimmunity Reviews, 2017, 16, 548-554.	2.5	44
122	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmunity Reviews, 2019, 18, 164-176.	2.5	44
123	Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology, 2010, 215, 756-761.	0.8	43
124	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	1.9	40
125	Complement Activation and Pregnancy Failure. Clinical Reviews in Allergy and Immunology, 2010, 39, 153-159.	2.9	39
126	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Frontiers in Cardiovascular Medicine, 2019, 6, 11.	1.1	39

#	Article	IF	Citations
127	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. Arthritis Care and Research, 2022, 74, 324-335.	1.5	39
128	Nuclear DNA Sensor IFI16 as Circulating Protein in Autoimmune Diseases Is a Signal of Damage that Impairs Endothelial Cells through High-Affinity Membrane Binding. PLoS ONE, 2013, 8, e63045.	1.1	39
129	The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity, 2009, 42, 257-259.	1.2	38
130	Pregnancy in autoimmune rheumatic diseases: The importance of counselling for old and new challenges. Autoimmunity Reviews, 2010, 10, 51-54.	2.5	38
131	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: â€~PROS' and â€~CONS'. Autoimmunity Reviews, 2012, 11, 577-580.	2.5	38
132	Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000785.	1.8	38
133	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care and Research, 2019, 71, 134-141.	1.5	37
134	Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. Rheumatology, 2012, 51, 2186-2190.	0.9	35
135	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
136	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nature Reviews Rheumatology, 2021, 17, 177-184.	3.5	35
137	Aspirinâ€Interleukinâ€3 Interrelationships in Patients With Antiâ€Phospholipid Syndrome. American Journal of Reproductive Immunology, 1996, 35, 80-84.	1.2	34
138	Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies. Frontiers in Immunology, 2018, 9, 864.	2.2	34
139	Autoantibodies and common idiotypes in men and women with sperm antibodies. American Journal of Obstetrics and Gynecology, 1988, 158, 596-603.	0.7	33
140	Neonatal effects of maternal antiphospholipid syndrome. Current Rheumatology Reports, 2009, 11, 70-76.	2.1	33
141	Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 2180-2185.	1.0	33
142	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic <i>Lupus erythematosus </i> . Autoimmunity, 2013, 46, 363-368.	1,2	33
143	Management of Recurrent Thrombosis in Antiphospholipid Syndrome. Current Rheumatology Reports, 2014, 16, 405.	2.1	33
144	The Pathogenicity of Anti- \hat{l}^2 2GP1-lgG Autoantibodies Depends on Fc Glycosylation. Journal of Immunology Research, 2015, 2015, 1-12.	0.9	33

#	Article	IF	CITATIONS
145	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Frontiers in Immunology, 2019, 10, 1948.	2.2	33
146	Immune System Development in Infants Born to Mothers with Autoimmune Disease, Exposed In Utero to Immunosuppressive Agents. American Journal of Perinatology, 2007, 24, 441-447.	0.6	32
147	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp> : Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	2.3	30
148	Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. Annals of the Rheumatic Diseases, 2020, 79, 943-950.	0.5	30
149	Anticardiolipin and anti-ß2GPI antibodies in a large series of European patients with systemic lupus erythematosus: Prevalence and clinical associations. Scandinavian Journal of Rheumatology, 1999, 28, 344-351.	0.6	29
150	Overview on Anticardiolipin ELISA Standardization. Journal of Autoimmunity, 2000, 15, 195-197.	3.0	29
151	Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis. Joint Bone Spine, 2018, 85, 317-322.	0.8	29
152	Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstetricia Et Gynecologica Scandinavica, 1994, 73, 389-392.	1.3	28
153	Evaluation of Current Methods for the Measurement of Serum Anti Double-Stranded DNA Antibodies. Annals of the New York Academy of Sciences, 2007, 1109, 401-406.	1.8	28
154	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000786.	1.8	28
155	Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thrombosis and Haemostasis, 2002, 88, 66-73.	1.8	28
156	Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures. Immunologic Research, 2017, 65, 150-156.	1.3	27
157	Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship. Current Rheumatology Reviews, 2019, 15, 177-188.	0.4	27
158	Neonates born from mothers with autoimmune disorders. Early Human Development, 2009, 85, S67-S70.	0.8	26
159	The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clinical Reviews in Allergy and Immunology, 2017, 52, 88-98.	2.9	26
160	The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: A narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines. Autoimmunity Reviews, 2020, 19, 102592.	2.5	26
161	Are the Current Attempts at Standardization of Antiphospholipid Antibodies Still Useful? Emerging Technologies Signal a Shift in Direction. Seminars in Thrombosis and Hemostasis, 2008, 34, 356-360.	1.5	25
162	Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases. Journal of Rheumatology, 2009, 36, 1744-1748.	1.0	25

#	Article	IF	CITATIONS
163	Effect of pregnancy on serum cytokines in SLE patients. Arthritis Research and Therapy, 2012, 14, R66.	1.6	25
164	Beyond the "syndrome― Antiphospholipid antibodies as risk factors. Arthritis and Rheumatism, 2012, 64, 342-345.	6.7	25
165	Should we treat congenital heart block with fluorinated corticosteroids?. Autoimmunity Reviews, 2017, 16, 1115-1118.	2.5	25
166	"Disease knowledge index―and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
167	Neutrophil Extracellular Traps in the Autoimmunity Context. Frontiers in Medicine, 2021, 8, 614829.	1.2	25
168	Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity, 2013, 46, 302-306.	1.2	24
169	A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?. Clinical Rheumatology, 2016, 35, 2117-2123.	1.0	24
170	Autoimmunity and Pregnancy: Autoantibodies and Pregnancy in Rheumatic Diseases. Annals of the New York Academy of Sciences, 2006, 1069, 346-352.	1.8	23
171	Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology, 2011, 50, 674-681.	0.9	23
172	Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab. Frontiers in Pharmacology, 2019, 10, 433.	1.6	23
173	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
174	The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases. American Journal of Reproductive Immunology, 2016, 75, 654-660.	1.2	22
175	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina ClÃnica, 2018, 151, 215-222.	0.3	22
176	Update on Antiphospholipid Syndrome: Ten Topics in 2017. Current Rheumatology Reports, 2018, 20, 15.	2.1	22
177	Decreased circulating T regulatory lymphocytes in obese patients undergoing bariatric surgery. PLoS ONE, 2018, 13, e0197178.	1.1	22
178	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. Autoimmunity Reviews, 2020, 19, 102525.	2.5	22
179	Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–GoutiÔres Syndrome. Journal of Clinical Immunology, 2016, 36, 693-699.	2.0	21
180	Relationship Between Different Subpopulations of Circulating CD4+ T-lymphocytes and Microvascular Structural Alterations in Humans. American Journal of Hypertension, 2017, 30, 51-60.	1.0	21

#	Article	IF	CITATIONS
181	Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events. Arthritis Care and Research, 2018, 70, 1277-1283.	1.5	21
182	IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000787.	1.8	21
183	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
184	Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. Rheumatology, 2021, 60, 5610-5619.	0.9	21
185	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus, 2021, 30, 2276-2285.	0.8	21
186	Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a â€~systemic disease'. Best Practice and Research in Clinical Rheumatology, 2012, 26, 79-90.	1.4	20
187	Pregnancy and reproductive aspects of systemic lupus erythematosus. Current Opinion in Rheumatology, 2017, 29, 473-479.	2.0	20
188	Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Israel Medical Association Journal, 2014, 16, 651-3.	0.1	20
189	Vitamin D and systemic lupus erythematous: a review of immunological and clinical aspects. Clinical and Experimental Rheumatology, 2018, 36, 153-162.	0.4	20
190	C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. NeuroMolecular Medicine, 2019, 21, 150-159.	1.8	19
191	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	1.8	19
192	Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatology International, 2015, 35, 1571-1573.	1.5	18
193	Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients. Journal of Translational Medicine, 2015, 13, 12.	1.8	18
194	Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1789-1798.	1.4	18
195	Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Autoimmunity Highlights, 2018, 9, 6.	3.9	18
196	Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clinical and Experimental Rheumatology, 2015, 33, 688-93.	0.4	18
197	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Science and Medicine, 2022, 9, e000651.	1.1	18
198	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis and Rheumatism, 2010, 62, 1201-1202.	6.7	17

#	Article	IF	CITATIONS
199	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. Biomedicines, 2021, 9, 671.	1.4	17
200	Gastrointestinal-associated autoantibodies in different autoimmune diseases. American Journal of Clinical and Experimental Immunology, 2012, 1, 49-55.	0.2	17
201	The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic. Clinical and Experimental Rheumatology, 2017, 35, 929-935.	0.4	17
202	Anti- \hat{l}^2 2 Glycoprotein I Antibodies Prevent the De-activation of Platelets and Sustain their Phagocytic Clearance. Journal of Autoimmunity, 2000, 15, 469-477.	3.0	16
203	Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: Comment on the article by Erkan et al. Arthritis and Rheumatism, 2002, 46, 1126-1127.	6.7	16
204	Epigenetics, pregnancy and autoimmune rheumatic diseases. Autoimmunity Reviews, 2020, 19, 102685.	2.5	16
205	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. Seminars in Arthritis and Rheumatism, 2020, 50, 1387-1393.	1.6	16
206	Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clinical and Experimental Rheumatology, 2017, 35, 303-308.	0.4	16
207	Antiphospholipid Antibodies and Endothelial Cells. Lupus, 1994, 3, 267-269.	0.8	15
208	Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). Autoimmunity, 2011, 44, 90-97.	1.2	15
209	Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety. Journal of Rheumatology, 2015, 42, 193-195.	1.0	15
210	Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatology Advances in Practice, 2020, 4, rkaa017.	0.3	15
211	Inherited thrombophilia in women with poor aPLâ€related obstetric history: prevalence and outcomes. Survey of 208Âcases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. American Journal of Reproductive Immunology, 2016, 76, 164-171.	1.2	14
212	Autoimmune diseases and pregnancy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101322.	2.2	14
213	Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays. Thrombosis and Haemostasis, 2005, 94, 665-72.	1.8	14
214	Systemic lupus erythematosus in pregnancy. Lancet, The, 1991, 338, 756-757.	6.3	13
215	Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis. Journal of Investigative Medicine, 2012, 60, 1204-1208.	0.7	13
216	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. Rheumatology, 2022, 61, SI136-SI142.	0.9	13

#	Article	IF	CITATIONS
217	Antirheumatic drugs and reproduction in women and men with chronic arthritis: TableÂ1. RMD Open, 2015, 1, e000048.	1.8	12
218	Obstetric Anti-phospholipid Syndrome: State of the Art. Current Rheumatology Reports, 2018, 20, 59.	2.1	12
219	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clinical and Experimental Rheumatology, 2022, 40, 3-11.	0.4	12
220	Effect of antihypertensive treatment with lercanidipine on endothelial progenitor cells and inflammation in patients with mild to moderate essential hypertension. Blood Pressure, 2016, 25, 337-343.	0.7	11
221	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 572876.	2.2	11
222	The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al Clinical Rheumatology, 2020, 39, 2489-2490.	1.0	11
223	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39, 25-28.	0.4	11
224	Complement Cascade in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2009, 1173, 427-434.	1.8	10
225	Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti–Tumor Necrosis Factorâ€Î± Therapy. Clinical Cardiology, 2014, 37, 738-743.	0.7	10
226	Relationship between different subpopulations of circulating CD4+ T lymphocytes and microvascular or systemic oxidative stress in humans. Blood Pressure, 2017, 26, 237-245.	0.7	10
227	Undifferentiated connective tissue disease, fibromyalgia and the environmental factors. Current Opinion in Rheumatology, 2017, 29, 355-360.	2.0	10
228	Winter lupus flares are associated with low vitamin D levels in a retrospective longitudinal study of Italian adult patients. Clinical and Experimental Rheumatology, 2015, 33, 153-8.	0.4	10
229	Cerebral ultrasound abnormalities in infants born to mothers with autoimmune disease. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2011, 96, F355-F358.	1.4	9
230	The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus. Prenatal Diagnosis, 2015, 35, 447-452.	1.1	9
231	Sine causa tetraparesis. Medicine (United States), 2018, 97, e13893.	0.4	9
232	Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 369-378.	1.0	9
233	Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 989.	2.2	9
234	Human leukocyte antigens class II in CIDP spectrum neuropathies. Journal of the Neurological Sciences, 2019, 407, 116533.	0.3	9

#	Article	IF	CITATIONS
235	An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. Rheumatology Advances in Practice, 2019, 3, rkz005.	0.3	9
236	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Annals of the Rheumatic Diseases, 2021, 80, 1175-1182.	0.5	9
237	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	0.9	9
238	Can we use NOACS in APS?. Autoimmunity Reviews, 2019, 18, 102408.	2.5	8
239	Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?. European Journal of Internal Medicine, 2020, 73, 76-82.	1.0	8
240	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq0	0 OrgBT /	Overlock 10 T
241	Improved Pregnancy Outcome in Patients With Rheumatoid Arthritis Who Followed an Ideal Clinical Pathway. Arthritis Care and Research, 2021, 73, 166-172.	1.5	8
242	Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes. European Journal of Anaesthesiology, 2021, 38, 916-922.	0.7	8
243	The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy. Clinical and Experimental Rheumatology, 2015, 33, 681-7.	0.4	8
244	The Course of Rheumatic Diseases During Pregnancy. Israel Medical Association Journal, 2019, 21, 464-470.	0.1	8
245	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres. Clinical and Experimental Rheumatology, 2022, 40, 19-26.	0.4	8
246	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clinical and Experimental Rheumatology, 2021, 39, 91-97.	0.4	8
247	Anti-IgA Antibodies in Two Brothers with Selective Serum IgA Deficiency. Acta Haematologica, 1975, 54, 312-320.	0.7	7
248	Comparison of pathologic and normal sera by immune complex determination: Five disease groups within 190 samples are discriminated by computer-selected combinations of 13 methods. Clinical Immunology and Immunopathology, 1984, 32, 298-315.	2.1	7
249	Elastic properties of the ascending aorta in patients with rheumatoid arthritis. International Journal of Cardiology, 2011, 150, 368-369.	0.8	7
250	Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. Clinical Rheumatology, 2016, 35, 1065-1069.	1.0	7
251	Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. Lupus, 2019, 28, 1074-1081.	0.8	7
252	Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. Clinical Rheumatology, 2019, 38, 609-610.	1.0	6

#	Article	IF	Citations
253	Long-term outcome of children born from mothers with autoimmune diseases. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 107-116.	1.4	6
254	Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic. Clinical Rheumatology, 2021, 40, 239-244.	1.0	6
255	Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study. Autoimmunity Reviews, 2021, 20, 102757.	2.5	6
256	Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2023, 64, 321-342.	2.9	6
257	Circulating Immune Complexes in Human Acute Leukaemia. British Journal of Haematology, 1981, 49, 269-274.	1.2	5
258	Development of Automated Assays for Anticardiolipin Antibodies Determination: Addressing Antigen and Standardization Issues. Annals of the New York Academy of Sciences, 2007, 1109, 493-502.	1.8	5
259	European Forum on Antiphospholipid Antibodies: research in progress. Lupus, 2009, 18, 924-929.	0.8	5
260	Anti-phospholipid antibodies. Rheumatology, 2014, 53, 201-202.	0.9	5
261	Incidence and prevalence of systemic sclerosis in Valcamonica, Italy, during an 18-year period. Journal of Scleroderma and Related Disorders, 2020, 5, 51-56.	1.0	5
262	Onset of idiopathic recurrent pericarditis during pregnancy. Journal of Cardiovascular Medicine, 2020, 21, 393-395.	0.6	5
263	The Influence of Treatment of Inflammatory Arthritis During Pregnancy on the Long-Term Children's Outcome. Frontiers in Pharmacology, 2021, 12, 626258.	1.6	5
264	Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. Frontiers in Pharmacology, 2021, 12, 666971.	1.6	5
265	Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 6157-6164.	0.7	5
266	Transverse Myelitis Activation Post-H1N1 Immunization: A Case of Adjuvant Induction?. Israel Medical Association Journal, 2015, 17, 120-2.	0.1	5
267	Managing puerperium in patients with systemic autoimmune diseases: an update. Expert Review of Clinical Immunology, 2022, 18, 391-399.	1.3	5
268	Anti-Cardiolipin and Anti-beta2-Glycoprotein I Antibodies: Performance of New Commercial ELISA Kits. Annals of the New York Academy of Sciences, 2007, 1109, 531-537.	1.8	4
269	Antinuclear Antibody Test: When to Order?. American Journal of Medicine, 2013, 126, e17.	0.6	4
270	"APS pregnancy – The offspring― Lupus, 2020, 29, 1336-1345.	0.8	4

#	Article	IF	CITATIONS
271	The pathogenic role of circulating Hashimoto's Thyroiditisâ€derived TPOâ€positive IgG on fetal loss in naà ve mice. American Journal of Reproductive Immunology, 2021, 85, e13331.	1.2	4
272	Antiphospholipid syndrome and antiphospholipid antibodies in children: the two sides of the coin. Israel Medical Association Journal, 2012, 14, 310-2.	0.1	4
273	Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abatacept. Clinical and Experimental Rheumatology, 2018, 36, 685.	0.4	4
274	Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study. Lupus Science and Medicine, 2022, 9, e000714.	1.1	4
275	Nature of the Antigammaglobulin Activity in Cryoglobulinemic Disorders. Acta Haematologica, 1974, 51, 159-169.	0.7	3
276	Response to: $\hat{a} \in C$ or respondence on $\hat{a} \in E$ LLAR recommendations for the management of antiphospholipid syndrome in adults $\hat{a} \in E$ by Zhou <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e249-e249.	0.5	3
277	Impact of COVID-19 on outpatient therapy with iloprost for systemic sclerosis digital ulcers. Journal of Scleroderma and Related Disorders, 2021, 6, 109-110.	1.0	3
278	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests., 2017, , 171-187.		3
279	Neuropsychiatric Outcome of Children Born to Women With Systemic Lupus Erythematosus and Exposed in Utero to Azathioprine: A Case-Control Study. Frontiers in Pharmacology, 2020, 11, 613239.	1.6	3
280	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 25-28.	0.4	3
281	Changes to expert opinion in the use of antirheumatic drugs before and during pregnancy five years after EULAR: points to consider. Rheumatology, 2022, 61, e331-e333.	0.9	3
282	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina ClÃnica (English Edition), 2018, 151, 215-222.	0.1	2
283	A guide to managing reproductive health in rheumatology. Nature Reviews Rheumatology, 2020, 16, 411-412.	3.5	2
284	Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus. Expert Opinion on Drug Safety, 2021, 20, 523-536.	1.0	2
285	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
286	Antibodies against antigens related to scleroderma in a cohort of patients with morphea. Italian Journal of Dermatology and Venereology, 2018, 153, 451-458.	0.1	2
287	Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors. Clinical and Experimental Rheumatology, 2016, 34, 352.	0.4	2
288	Detection of Circulating Immune Complexes in Acute Non-Lymphatic Leukaemia: Is It Reliable?. Acta Haematologica, 1983, 69, 404-408.	0.7	1

#	Article	IF	CITATIONS
289	Non-organ Specific Autoimmunity Involvement in Cardiovascular Disease. Handbook of Systemic Autoimmune Diseases, 2003, 1, 41-51.	0.1	1
290	25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. Internal and Emergency Medicine, 2009, 4, 165-167.	1.0	1
291	Update on antiphospholipid antibodies: clinical significance. International Journal of Clinical Rheumatology, 2009, 4, 551-560.	0.3	1
292	Chapter 9 Obstetric Manifestations of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2009, 10, 117-124.	0.1	1
293	Anti-MJ/NXP-2 antibodies are the most common specificty in a cohort of adult caucasian patients with dermatomyositis. Annals of the Rheumatic Diseases, 2012, 71, A49.2-A49.	0.5	1
294	Treatment and functional outcome of patients with cystoid macular edema: a single-center experience. Clinical Rheumatology, 2015, 34, 791-794.	1.0	1
295	Systemic Vasculitis and Pregnancy. , 2016, , 213-224.		1
296	SAT0127â€LONG-TERM OUTCOME OF CHILDREN BORN TO MOTHERS WITH CHRONIC ARTHRITIS AND EXPOSE TO TNF-INHIBITORS DURING PREGNANCY: A CASE-CONTROL STUDY. , 2019, , .	ED	1
297	AB0668â€ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY AND BREAST IMPLANTS RUPTURE IN ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		1
298	FRIO387â€DISEASE COURSE AND OUTCOMES DURING PREGNANCY IN PATIENTS WITH AXIAL SPONDILOARTHRITIS: COMPARISON BETWEEN TNFI USERS AND NAIVE PATIENTS. , 2019, , .		1
299	Response to: †Correspondence on †EULAR recommendations for the management of antiphospholipid syndrome in adults†M†Mae by Gao and Qin. Annals of the Rheumatic Diseases, 2023, 82, e107-e107.	0.5	1
300	Long-Term Outcome of Children of Rheumatic Disease Patients. , 2014, , 289-303.		1
301	Malignancies: a possible "first hit" in the development of catastrophic antiphospholipid syndrome?. Israel Medical Association Journal, 2014, 16, 583-4.	0.1	1
302	Management of Gender-Related Problems in Women with Autoimmune Rheumatic Diseases. Israel Medical Association Journal, 2016, 18, 183-7.	0.1	1
303	Management of maternal antiphospholipid syndrome. Clinical and Experimental Rheumatology, 2020, 38, 149-156.	0.4	1
304	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clinical and Experimental Rheumatology, 2021, 39, 91-97.	0.4	1
305	Pregnancy in Rheumatoid Arthritis, Sjögren Syndrome and Other Rare Autoimmune Rheumatic Diseases. Handbook of Systemic Autoimmune Diseases, 2005, 4, 77-93.	0.1	O
306	Offspring of Women with Systemic Autoimmune Diseases: Fetal and Neonatal Complications and Inheritance of Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases, 2005, 4, 111-121.	0.1	0

#	Article	IF	CITATIONS
307	Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome. Current Rheumatology Reviews, 2010, 6, 18-24.	0.4	0
308	Current treatment strategies for management of antiphospholipid syndrome. Expert Opinion on Orphan Drugs, 2014, 2, 205-215.	0.5	0
309	Dr. Reggia, <i>et al,</i> reply. Journal of Rheumatology, 2015, 42, 1995.1-1995.	1.0	O
310	Identifying and managing lupus nephritis during pregnancy. Expert Opinion on Orphan Drugs, 2016, 4, 1021-1031.	0.5	0
311	Obstetric Manifestations of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 107-120.	0.1	O
312	SAT0027â€CIRCULATING CD3+CD31+CXCR4+ T CELLS IN RHEUMATOID ARTHRITIS PATIENTS: CORRELATION V. RETINAL MICROVASCULAR DAMAGE AND POTENTIAL EFFECT OF ABATACEPT THERAPY., 2019,,.	NITH	0
313	ABO481â€AUTOANTIBODIES' TITRE MODULATION BY ANTI-BLYS TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		O
314	AB1289â€TESTING DIFFERENT ITEMS INCLUDED IN THE DEFINITION OF REMISSION IN A MULTICENTRE SLE COHORT. , 2019, , .		0
315	FRIO607â€IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		O
316	FRIO185â€HYDROXYCHLOROQUINE FOR THE PREVENTION OF RELAPSES IN A SERIES OF 812 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE HIBISCUS RETROSPECTIVE STUDY., 2019,,.		0
317	03â€Family planning and SLE: from conception through child-bearing. , 2019, , .		O
318	P136â€SLEDAI response prediction to belimumab therapy by baseline levels of BLyS, APRIL and CD8+ effector memory T-cells. , 2020, , .		0
319	Maternal, pregnancy and neonatal outcomes of twin gestations in women with rheumatic diseases: A single-center, case-control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 264, 49-55.	0.5	O
320	Autoimmune Rheumatic Disorders in Pregnancy. , 2021, , 295-303.		0
321	Pregnancy in antiphospholipid syndrome: can we improve patient management?. Israel Medical Association Journal, 2014, 16, 614-5.	0.1	O
322	Preface. What's New in Autoimmunity: New Autoantibodies, New Therapies, New Diseases. Israel Medical Association Journal, 2015, 17, 71-3.	0.1	0
323	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). Thrombosis and Haemostasis, 2022, 122, 1612-1620.	1.8	O
324	Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners Clinical and Experimental Rheumatology, 2022, , .	0.4	0

#	Article	lF	CITATIONS
325	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres Clinical and Experimental Rheumatology, 2022, , .	0.4	o
326	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET Clinical and Experimental Rheumatology, 2022, , .	0.4	0